These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15063658)

  • 1. Practical robust fit of enzyme inhibition data.
    Kuzmic P; Hill C; Janc JW
    Methods Enzymol; 2004; 383():366-81. PubMed ID: 15063658
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.
    Copeland RA
    Methods Biochem Anal; 2005; 46():1-265. PubMed ID: 16350889
    [No Abstract]   [Full Text] [Related]  

  • 3. A steady state mathematical model for stepwise "slow-binding" reversible enzyme inhibition.
    Kuzmic P
    Anal Biochem; 2008 Sep; 380(1):5-12. PubMed ID: 18206642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants.
    Kuzmic P; Sideris S; Cregar LM; Elrod KC; Rice KD; Janc JW
    Anal Biochem; 2000 May; 281(1):62-7. PubMed ID: 10847611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classification of cytochrome P450 inhibitors with respect to binding free energy and pIC50 using common molecular descriptors.
    Dagliyan O; Kavakli IH; Turkay M
    J Chem Inf Model; 2009 Oct; 49(10):2403-11. PubMed ID: 19777996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).
    Ulmschneider S; Negri M; Voets M; Hartmann RW
    Bioorg Med Chem Lett; 2006 Jan; 16(1):25-30. PubMed ID: 16246562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition and induction of human cytochrome P450 enzymes: current status.
    Pelkonen O; Turpeinen M; Hakkola J; Honkakoski P; Hukkanen J; Raunio H
    Arch Toxicol; 2008 Oct; 82(10):667-715. PubMed ID: 18618097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Sutin L; Andersson S; Bergquist L; Castro VM; Danielsson E; James S; Henriksson M; Johansson L; Kaiser C; Flyrén K; Williams M
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4837-40. PubMed ID: 17600707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
    Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
    ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring QSAR for substituted 2-sulfonyl-phenyl-indol derivatives as potent and selective COX-2 inhibitors using different chemometrics tools.
    Khoshneviszadeh M; Edraki N; Miri R; Hemmateenejad B
    Chem Biol Drug Des; 2008 Dec; 72(6):564-74. PubMed ID: 19090923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
    Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
    Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors.
    Akritopoulou-Zanze I; Darczak D; Sarris K; Phelan KM; Huth JR; Song D; Johnson EF; Jia Y; Djuric SW
    Bioorg Med Chem Lett; 2006 Jan; 16(1):96-9. PubMed ID: 16216502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of scoring functions on a diverse test set.
    Cheng T; Li X; Li Y; Liu Z; Wang R
    J Chem Inf Model; 2009 Apr; 49(4):1079-93. PubMed ID: 19358517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput screening of enzyme inhibitors: simultaneous determination of tight-binding inhibition constants and enzyme concentration.
    Kuzmic P; Elrod KC; Cregar LM; Sideris S; Rai R; Janc JW
    Anal Biochem; 2000 Nov; 286(1):45-50. PubMed ID: 11038272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic basis of enzyme-targeted drugs.
    Robertson JG
    Biochemistry; 2005 Apr; 44(15):5561-71. PubMed ID: 15823014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling.
    Zheng M; Zheng M; Ye D; Deng Y; Qiu S; Luo X; Chen K; Liu H; Jiang H
    Bioorg Med Chem Lett; 2007 May; 17(9):2414-20. PubMed ID: 17336065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theoretical analysis of peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase: Insight into the mechanism of inhibition and the application of QM/MM calculations in structure-based drug design.
    Gleeson MP; Hillier IH; Burton NA
    Org Biomol Chem; 2004 Aug; 2(16):2275-80. PubMed ID: 15305206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).
    Du QS; Huang RB; Wei YT; Du LQ; Chou KC
    J Comput Chem; 2008 Jan; 29(2):211-9. PubMed ID: 17559075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.